Mirati Therapeutics

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Mirati Therapeutics reports successful KRAZATI launch amidst financial challenges

Mirati Therapeutics had a transformative year with the successful launch of KRAZATI for KRAS G12C mutated lung cancer.
Despite a net loss in Q4 2022, the company ended the year with a strong cash position and positive market feedback.
Challenges include financial losses, maximizing target inhibition with PRMT5 inhibitors, and regulatory hurdles for Phase 3 trials.
Opportunities lie in collaborations, combination therapies, Phase 3 trials, and advancing pipeline products for future growth.

Mirati Therapeutics reports strong Q1 performance and advances pipeline

Mirati Therapeutics showcased a strong financial performance in Q1 2023, driven by the successful launch of KRAZATI and progress in clinical studies for MRTX1133. The company's commitment to advancing its pipeline and addressing inquiries from analysts reflects a strategic focus on innovation and stakeholder engagement. Despite facing challenges such as a significant net loss, Mirati remains well-positioned with a robust cash position and promising growth opportunities.

Mirati Therapeutics reports strong Q2 performance and navigates strategic challenges

Mirati Therapeutics showcased strong commercial performance, promising clinical data, and proactive financial management strategies in its Q2 2023 Earnings Call.
While facing challenges in market positioning, trial complexities, and operational management, the company remains well-positioned to capitalize on opportunities in advancing its pipeline and optimizing financial performance.
Analysts' inquiries highlighted key areas of interest and concern, signaling the importance of strategic decision-making, regulatory navigation, and competitive positioning for Mirati's future success.
Overall, Mirati's focus on innovation, patient outcomes, and financial sustainability underscores its commitment to driving therapeutic advancements, addressing unmet medical needs, and delivering long-term value to stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mirati Therapeutics Inc is a Biotechnology company located in 9363 Towne Centre Dr, San Diego, CA, United States.

The company presented phase 2 data from its non-small cell lung cancer therapy.

Why Shares of Mirati Therapeutics Fell Wednesday

Mirati Therapeutics' (MRTX) preliminary data from the first-line NSCLC study showed that adagrasib plus Merck's Keytruda achieved an objective response rate of 49%.

Mirati (MRTX) Down After 1st-Line Lung Cancer Data on Adagrasib

Investors and analysts were unimpressed by trial results on the company's combination therapy to treat non-small cell lung cancer.

Why Shares of Mirati Therapeutics Fell Tuesday

Amgen

Mirati said almost half of patients responded to its lung cancer regimen, but MRTX stock crashed on questions about its market opportunity. The post Mirati Therapeutics Crashes As The Cancer Rivalry With Amgen Heats Up appeared first on Investor's Business Daily.

Mirati Therapeutics Crashes As The Cancer Rivalry With Amgen Heats Up

Adagrasib in combination with pembrolizumab demonstrates favorable tolerability and promising preliminary efficacy in patients with first-line advanced/metastatic NSCLC harboring a KRASG12C mutation Findings will be presented on December 7 at the 2022 ESMO Immuno-Oncology Annual Congress, as an oral presentation from 2:05 p.m.-2:15 p.m. CET / 8:05 a.m.

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Evaluating Investigational Sitravatinib in Combination with Nivolumab for Patients with Non-Squamous Non-Small Cell Lung Cancer with Acquired Resistance to Chemotherapy and Immune Checkpoint Inhibitor Therapy SAN DIEGO , Dec. 2, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that based on the results of an interim analysis on overall survival, the registrational Phase 3 study evaluating sitravatinib in combination with nivolumab (OPDIVO®)1 in patients with second or third line non-squamous non-small cell lung cancer (NSQ-NSCLC) who have acquired resistance to prior therapy with chemotherapy and immune checkpoint inhibitor therapy (SAPPHIRE) will continue to the study's final analysis. The final analysis is expected to be reached in mid-2023.

Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study

SAN DIEGO , Nov. 28, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced a late-breaking presentation of concurrent combination results of adagrasib and pembrolizumab in first line advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. Findings will be presented on December 7 at the 2022 European Society of Medical Oncology Immuno-Oncology (ESMO IO) Annual Congress as an oral presentation from 2:15 p.m.

Mirati Therapeutics to Present Late-Breaking Combination Results and Host Virtual Investor Relations Event at ESMO IO

Mirati Therapeutics' (MRTX) new drug application (NDA), seeking approval for adagrasib, its KRAS inhibitor drug, for previously-treated KRASG12C-mutated NSCLC is under review with the FDA with a decision expected by Dec 14.

Mirati's (MRTX) Stock Rallies 11% on Buyout Speculations

Big Pharma suitors could be looking to buy Mirati Therapeutics, according to reports that sent MRTX stock close to a breakout Wednesday. The post Mirati Therapeutics Surges As Big Pharma Reportedly Preps For A Buyout Battle appeared first on Investor's Business Daily.

Mirati Therapeutics Surges As Big Pharma Reportedly Preps For A Buyout Battle

Mirati Therapeutics (NASDAQ: MRTX ) stock is a hot topic on Wednesday as the cancer drugmaker considers a potential takeover. According to insider sources, several large pharmaceutical companies are showing interest in acquiring Mirati Therapeutics.

MRTX Stock Alert: What to Know as Mirati Therapeutics Considers Potential Takeover

Mirati Therapeutics (MRTX) reports narrower-than-expected Q3 loss. Revenues also beat the mark.

Mirati's (MRTX) Stock Rises on Q3 Earnings and Sales Beat

Mirati Therapeutics, Inc. (NASDAQ:MRTX ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Ryan Asay - Vice President of Corporate Affairs David Meek - Chief Executive Officer Charles Baum - President, Founder & Head of Research & Development Laurie Stelzer - Chief Financial Officer James Christensen - Chief Scientific Officer Ben Hickey - Chief Commercial Officer Alan Sandler - Chief Medical Officer Conference Call Participants Salveen Richter - Goldman Sachs Tyler Van Buren - Cowen Gena Wang - Barclays Jonathan Miller - Evercore ISI Michael Schmidt - Guggenheim Michael Ulz - Morgan Stanley Jason Gerberry - Bank of America Maury Raycroft - Jefferies Eric Joseph - JPMorgan Benjamin Burnett - Stifel Andrew Berens - SVB Securities Yigal Nochomovitz - Citigroup Silvan Tuerkcan - JMP Securities Jay Olson - Oppenheimer Swapnil Malekar - Piper Sandler Kalpit Patel - B. Riley Securities Operator Good afternoon, and welcome to the Mirati Therapeutics Third Quarter 2022 Earnings Call.

Mirati Therapeutics, Inc. (MRTX) Q3 2022 - Earnings Call Transcript

Mirati (MRTX) delivered earnings and revenue surprises of 10.69% and 15.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates

SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of 2022 and recent corporate updates. "In the third quarter, we made notable advancements within our targeted oncology portfolio, while executing on strategic priorities to position Mirati for continued success," said  David Meek , chief executive officer, Mirati Therapeutics, Inc. "The fourth quarter includes several exciting milestones for Mirati, including our anticipated Prescription Drug User Fee Act (PDUFA) date for adagrasib, which we are prepared to launch upon approval, the release of topline interim data for our phase 3 SAPPHIRE study, and an expected update on our KRYSTAL-7 first-line non-small cell lung cancer (NSCLC) study in combination with pembrolizumab.

Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates

Charles M. Baum, M.D., Ph.D., President, Founder and head of R&D to retire 2Q 2023 following over a decade of Mirati leadership, driving corporate transformation SAN DIEGO , Nov. 8, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of Alan Sandler, M.D.

Mirati Therapeutics Appoints Alan Sandler, M.D., as Executive Vice President and Chief Medical Officer, Shares Update to Executive Leadership Team

Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Mirati (MRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

SAN DIEGO , Oct. 25, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the third quarter of 2022 along with recent corporate updates on November 8, 2022. During a conference call at 4:30 p.m.

Mirati Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Updates

Aadi Bioscience

SAN DIEGO and LOS ANGELES , Oct. 12, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company, and Aadi Bioscience, Inc. (Nasdaq: AADI), a commercial stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced a clinical collaboration to evaluate the combination of adagrasib, a KRASG12C selective inhibitor, and nab-sirolimus, a small molecule mTOR inhibitor complexed with human albumin in KRAS G12C mutant non-small cell lung cancer (NSCLC) and other solid tumors. The primary objective of this multi-center, single-arm, open-label Phase 1/2 trial is to determine the optimal dose and recommended Phase 2 dose for the combination of adagrasib and nab-sirolimus in patients with KRASG12C - mutant solid tumors.

Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation

Biogen

Gilead Sciences

All four of these drugmakers are expecting important FDA approval decisions over the next few months.

4 Biotech Stocks With Huge Incoming Catalysts

Amgen's KRAS targeting drug Lumakras has now been approved in the US and Europe, making $77m sales in Q222. Mirati Therapeutics also has a KRAS targeting drug which may well win approval in December in the same indication as Lumakras - NSCLC.

Amgen Vs. Mirati: Playing To Win In KRAS Mutated Lung Cancer

Heron Therapeutics

Novavax

Here are the upcoming catalysts for Mirati Therapeutics, Novavax, and Heron Therapeutics.

3 Stocks Expecting Good News From the FDA

VanEck Vectors Biotech ETF

Chemocentryx

Invesco Dow Jones Industrial Average Dividend ETF

iShares Nasdaq Biotechnology ETF

Cancer-drug maker Amgen solidified its position in a highly competitive market by acquiring its rival Mirati Therapeutics.

Cancer-Drug Maker's Solid Position And Successful Drug Record Drive Growth

Mirati has strong competitive differences against larger rival Amgen. However, lead indication, 2nd line NSCLC, is not where these differences will come out.

Mirati: A Potential Blockbuster Stock, Will Need Patience

Adagrasib demonstrates promising clinical efficacy and favorable tolerability as a monotherapy and in combination with cetuximab in heavily pretreated patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation SAN DIEGO , Sept. 7, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from KRYSTAL-1, a multicohort Phase 1/2 study, evaluating adagrasib with or without cetuximab in patients with advanced CRC harboring a KRASG12C mutation.

Mirati Therapeutics Presents Late-Breaking Adagrasib Monotherapy and Combination Results in Advanced Colorectal Cancer

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?

News for Mirati Therapeutics Stock (MRTX)